摘要
背景:阿尔茨海默病(AD)是一种神经退行性疾病,其特征在于脑中的细胞外淀粉样蛋白斑和神经原纤维缠结(neurofibrillary tangles)。研究表明,神经元能够重新进入细胞周期,但还不足以完全复制。这导致细胞死亡和随后的神经变性。 目的:本研究旨在分析AD患者和正常人脑组织中MAPT基因和CDK5(细胞周期调控相关基因)的表达。 方法:采用实时定量PCR技术对26例AD患者和24例健康老年人脑内三个区域(内嗅皮层,听皮层和海马)的150个样本进行特征描述。 结果:当共同分析脑样品时,发现AD患者CDK5和MAPT基因表达降低。当各组样本按脑区分离并比较时,海马和内嗅皮层中CDK5的表达存在显着性差异。在这两种情况下,AD组mRNA均较低(p = 0.0001)。然而,使用MAPT基因的相同分析显示没有显着的统计学差异。当在每组中的大脑的不同区域之间比较基因表达时,没有发现统计学差异。 结论:这些结果可能有助于更好地理解CDK5和MAPT基因在AD中的参与,因为它们考虑了基于疾病进展而受到不同影响的不同大脑区域。主要挑战是在未来为这种使人衰弱的疾病建立有效的治疗方法。
关键词: 阿尔茨海默病,脑,CDK5,细胞周期,基因表达,MAPT。
Current Alzheimer Research
Title:CDK5 and MAPT Gene Expression in Alzheimer's Disease Brain Samples
Volume: 15 Issue: 2
关键词: 阿尔茨海默病,脑,CDK5,细胞周期,基因表达,MAPT。
摘要: Background: Alzheimer's disease (AD) is a neurodegenerative disorder characterized by extracellular amyloid plaque and neurofibrillary tangles in the brain. Studies have shown that neurons are able to re-enter the cell cycle, but not enough to enable full replication. This leads to cell death and consequent neurodegeneration.
Objective: This study aimed to characterize the expression of the MAPT gene and CDK5 (the gene involved in cell cycle regulation) in brain samples from patients with AD and controls.
Method: The real-time-PCR technique was used to characterize 150 samples from three areas of the brain (entorhinal cortex, auditory cortex, and hippocampus) of 26 AD patients and 24 healthy elderly subjects.
Results: When the brain samples were analyzed collectively, a decrease in CDK5 and MAPT gene expression was found in AD patients. When each groups' samples were separated by area of the brain and compared, significant differences were found in CDK5 expression in the hippocampus and the entorhinal cortex. In both cases, mRNA was lower in the AD group (p=0.0001); however, the same analysis using the MAPT gene revealed no significant statistical differences. No statistical differences were found when gene expression was compared between the different regions of the brain within each group.
Conclusion: These results may contribute to a better understanding of the involvement of CDK5 and MAPT genes in AD in that they consider different areas of the brain that are affected differently based on disease progression. The main challenge is to establish an effective therapy for this debilitating disease in the future.
Export Options
About this article
Cite this article as:
CDK5 and MAPT Gene Expression in Alzheimer's Disease Brain Samples, Current Alzheimer Research 2018; 15 (2) . https://dx.doi.org/10.2174/1567205014666170713160407
DOI https://dx.doi.org/10.2174/1567205014666170713160407 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Meet Our Editorial Board Member
CNS & Neurological Disorders - Drug Targets The Role of Vascular Factors in Late-Onset Sporadic Alzheimers Disease. Genetic and Molecular Aspects
Current Alzheimer Research Astrocyte Pathology in Major Depressive Disorder: Insights from Human Postmortem Brain Tissue
Current Drug Targets Disconnection of Language and Memory in Semantic Dementia: A Comparative and Theoretical Analysis
Current Alzheimer Research New Perspectives for the Diagnosis of Alzheimers Disease
Recent Patents on CNS Drug Discovery (Discontinued) Structure-Based Design, Synthesis and Molecular Modeling Studies of Thiazolyl Urea Derivatives as Novel Anti-Parkinsonian Agents
Medicinal Chemistry Therapeutic Advances in the Treatment of Alzheimer's Disease: Present and Future
Current Drug Therapy The Intracellular Domain of Amyloid Precursor Protein is a Potential Therapeutic Target in Alzheimer’s Disease
Current Drug Discovery Technologies Role of Nitric Oxide Signaling Pathways in Brain Injuries
Current Chemical Biology Cell-based Treatment of Cerebral Palsy: Still a Long Way Ahead
Current Stem Cell Research & Therapy Potential Therapeutic Benefits of Maintaining Mitochondrial Health in Peripheral Neuropathies
Current Neuropharmacology No Significant Effect of 7,8-Dihydroxyflavone on APP Processing and Alzheimer-Associated Phenotypes
Current Alzheimer Research The Classic Basic Protein of Myelin – Conserved Structural Motifs and the Dynamic Molecular Barcode Involved in Membrane Adhesion and Protein-Protein Interactions
Current Protein & Peptide Science Double-Faced Role of Human Mesenchymal Stem Cells and their Role/Challenges in Cancer Therapy
Current Stem Cell Research & Therapy Pharmacological Control of Autophagy: Therapeutic Perspectives in Inflammatory Bowel Disease and Colorectal Cancer
Current Pharmaceutical Design The Animal Models of Dementia and Alzheimer’s Disease for Pre-Clinical Testing and Clinical Translation
Current Alzheimer Research Exploring N<sup>1</sup>-p-Fluorobenzyl-Cymserine as an Inhibitor of 5-Lipoxygenase as a Candidate for Type 2 Diabetes and Neurodegenerative Disorder Treatment
CNS & Neurological Disorders - Drug Targets Epigenetics in Alzheimers Disease: a Focus on DNA Modifications
Current Pharmaceutical Design Cannabinoid-related Agents in the Treatment of Anxiety Disorders: Current Knowledge and Future Perspectives
Recent Patents on CNS Drug Discovery (Discontinued) Glutamate and Mitochondria: Two Prominent Players in the Oxidative Stress-Induced Neurodegeneration
Current Alzheimer Research